What were the main outcomes of Amgen's 2011 Annual Stockholders Meeting?

The main outcomes include the election of all 12 director nominees, the ratification of Ernst & Young LLP as independent auditors, the approval of an advisory vote on executive compensation, and shareholder approval for holding future advisory votes on executive compensation annually. Additionally, a shareholder proposal concerning action by written consent was also approved.

Were there any significant concerns raised by shareholders during the meeting based on the voting results?

While the advisory vote on executive compensation was approved, a substantial portion of shareholders voted against it (309,162,287 votes against out of 717,838,841 total votes cast), suggesting some shareholder concerns regarding the company's executive pay practices. The approval of the shareholder proposal on written consent also indicates a desire from some shareholders for more direct avenues for action.

What is the significance of the broker non-votes reported for most proposals?

Broker non-votes occur when a broker holds shares in "street name" for a beneficial owner and does not receive voting instructions from the owner. These votes are not counted towards the total votes cast for or against a proposal, but they are often considered when determining if a quorum is present or when calculating majority based on outstanding shares. Their presence, especially a consistent number across proposals, highlights the importance of shareholder participation and proxy voting.

What does the approval of the stockholder proposal on written consent mean for Amgen?

The approval of this proposal means that Amgen shareholders have expressed a preference for the company to allow for shareholder action by written consent. This could enable shareholders to take action outside of the annual meeting process, potentially increasing shareholder influence on certain corporate matters.

AMGN 8-K: Shareholder Matters

Summary

Amgen Inc. (AMGN) filed an 8-K report on May 23, 2011, detailing the results of its Annual Meeting of Stockholders held on May 20, 2011. The primary purpose of this filing was to inform investors about the outcomes of various shareholder votes. Key among these were the election of directors, the ratification of Ernst & Young LLP as the company's independent registered public accountants, and advisory votes on executive compensation and the frequency of future executive compensation votes. The report also disclosed the outcome of a specific stockholder proposal. Overall, the meeting reflected strong shareholder confidence in the company's board and accounting oversight, with advisory votes also generally aligning with management's proposals. For investors, the outcomes of the director elections and the ratification of auditors are crucial indicators of corporate governance and financial oversight stability. The advisory vote on executive compensation, while approved, shows a notable portion of shareholders expressing dissent, which could be a point of focus for future engagement. The overwhelming preference for a one-year frequency for future advisory votes on compensation indicates shareholder desire for regular oversight in this area. Finally, the approval of the shareholder proposal regarding action by written consent suggests a willingness by the company to consider certain shareholder-driven governance changes.

Key Highlights

1All 12 nominated directors were elected to serve a one-year term expiring at the 2012 Annual Meeting of Stockholders.
2Ernst & Young LLP was ratified as Amgen's independent registered public accountants for the fiscal year ending December 31, 2011.
3An advisory vote on executive compensation was approved by shareholders.
4Shareholders overwhelmingly supported holding future advisory votes on executive compensation on an annual basis (one year).
5A stockholder proposal regarding shareholder action by written consent was approved.
6The filing provides detailed vote counts for each proposal, including votes for, against, abstentions, and broker non-votes.

AMGEN INC 8-K Report, Shareholder Vote Results (May 23, 2011)

Summary

Key Highlights

Frequently Asked Questions